Previous 10 | Next 10 |
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into NRx Pharmaceuticals (NasdaqGM: NRXP) and provides the following update. In June 2021, ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into NRx Pharmaceuticals (NasdaqGM: NRXP). In June 2021, the Company announced that it f...
NRX PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXP NRX PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick &...
NRx Pharmaceuticals (NASDAQ:NRXP) said it filed a new request with the U.S. Food and Drug Administration (FDA) for breakthrough therapy designation for its COVID-19 drug Zyesami. The company said the filing for Zyesami (aviptadil) is for a subgroup of patients with critical COVID-19 ...
NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress PR Newswire Breakthrough Therap...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into NRx Pharmaceuticals (NasdaqGM: NRXP). In June 2021, the Company announced that it f...
Biopharmaceutical company NRx Pharmaceuticals (NASDAQ:NRXP) on Friday filed for resale of up to 7.82M shares of common stock by certain selling shareholders. The company is also registering 391,236 shares of common stock to be issued upon exercise of the placement agent options. The company w...
NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference PR Newswire Company to Present Corporate Update During Investor Webcast, April 14, 2022 , at 4:30pm ET RADNOR, Pa. , April 8, 20...
Relief Therapeutics (OTCQB:RLFTF) said it has entered into a stipulation to stay the proceedings in its pending litigation with NRx Pharmaceuticals' (NRXP) unit NeuroRx, and Jonathan Javitt to allow the parties to attempt to seek to mediate their dispute. The companies are embroiled...
NRx Pharmaceuticals, Inc. (NRXP) Q4 2021 Earnings Conference Call March 31 2022, 08:30 AM ET Company Participants Eric Goldstein - MD, LifeSci Advisors, IR Robert Besthof - Interim CEO, Head of Operations & Chief Commercial Officer Ira Strassberg - CFO and Treasurer Conference Call Partic...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...